Abstracts tagged "adalimumab and ankylosing spondylitis (AS)"

Abstract Number: 2622 • 2018 ACR/ARHP Annual Meeting
Regional and Temporal Variation in the Baseline Profile of Ankylosing Spondylitis Patients Initiating Adalimumab Following Failure of Non-Biologic Treatment in Canadian Routine Care
Louis Bessette^1,2, Majed Khraishi³, Viktoria Pavlova⁴, Brandusa Florica^5,6 and Valencia P. Remple^7,8, ¹Centre Hospitalier de l'Université Laval, Quebec, QC, Canada, ²Rheumatology, Laval University, Quebec, QC, Canada, ³Memorial University of Newfoundland, St. John's, NF, Canada, ⁴McMaster University, Hamilton, ON, Canada, ⁵Trillium Health Partners, Mississauga, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada, ⁸AbbVie Corporation, Montreal, QC, Canada
Background/Purpose: Treatment selection in Canadian routine clinical care is based on the judgment of the treating physician but is also affected by treatment guidelines and…
Abstract Number: 2847 • 2015 ACR/ARHP Annual Meeting
Predictors of Therapeutic Response in Ankylosing Spondylitis Patients Initiating Therapy with Adalimumab in a German Non-Interventional Study
Michaela Koehm^1,2, Frank Behrens^1,3, Eva C. Scharbatke⁴, Marc Schmalzing⁵, Holger Gnann⁶, Gerd Greger⁷, Bianca Wittig⁸, Hans Peter Tony⁹ and Harald Burkhardt^3,10, ¹Clinical Research, Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt/Main, Germany, ²Rheumatology, Goethe-University Frankfurt, Frankfurt/Main, Germany, ³Rheumatology, Goethe-University Frankfurt, Frankfurt, Germany, ⁴Rheumatology/Immunology, University of Würzburg, Würzburg, Germany, ⁵Rheumatology/Immunology, University Würzburg, Würzburg, Germany, ⁶Abteilung Biostatistik, GKM Gesellschaft für Therapieforschung mbH, München, Germany, ⁷AbbVie Deutschland GmbH & Co.KG, Wiesbaden, Germany, ⁸Abbott GmbH & Co KG, Wiesbaden, Germany, ⁹Rheumatology / Clinical Immunology, University Hospital Würzburg, Würzburg, Germany, ¹⁰Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt/Main, Germany
Background/Purpose: Ankylosing spondylitis (AS) is associated with a significant burden of illness and has limited treatment options. The identification of predictors of response to anti-tumor necrosis…
Abstract Number: 1509 • 2013 ACR/ARHP Annual Meeting
Immunogenicity, Adalimumab Levels and Clinical Response In Ankylosing Spondylitis Patients During 24 Weeks Of Follow-Up
Eva L. Kneepkens¹, James C. Wei², Michael T. Nurmohamed^3,4, Kai-Jieh Yeo⁵, CY Chen⁶, Irene E. van der Horst-Bruinsma^1,7, Desiree van der Kleij⁸, Theo Rispens⁹, Gertjan Wolbink^3,9 and Charlotte L. M. Krieckaert³, ¹Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ²Allergy/Immunology/Rheumatolog, Chung Shan Med Univ Hospital, Taichung, Taiwan, ³Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁴Rheumatology, VU University medical centre, Amsterdam, Netherlands, ⁵Division of Allergy, Immunology and Rheumatology, Chung Shan Med Univ Hospital, Taichung, Taiwan, ⁶Chung Shan Med Univ Hospital, Taichung, Taiwan, ⁷Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁸Sanquin Diagnostic Services, Amsterdam, Netherlands, ⁹Sanquin Research, Amsterdam, Netherlands
Background/Purpose: Immunogenicity influences adalimumab levels and therefore clinical response in patients with rheumatic diseases. Objectives: To study the relation between clinical response, adalimumab levels and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].